ABSTRACT
Cisplatin plays an important role in the therapy for human head and neck cancers. However, cancer cells develop cisplatin resistance, leading to difficulty in treatment and poor prognosis. To analyze cisplatin-resistant mechanisms, a cisplatin-resistant cell line, IMC-3CR, was established from the IMC-3 human maxillary cancer cell line. Flow cytometry revealed that, compared with IMC-3 cells, cisplatin more dominantly induced cell cycle G2/M arrest rather than apoptosis in IMC-3CR cells. That fact suggests that IMC-3CR cells avoid cisplatin-induced apoptosis through induction of G2/M arrest, which allows cancer cells to repair damaged DNA and survive. In the present study, we specifically examined Poly(rC)-Binding Protein 4 (PCBP4), which reportedly induces G2/M arrest. Results showed that suppression of PCBP4 by RNAi reduced cisplatin-induced G2/M arrest and enhanced apoptosis in IMC-3CR cells, resulting in the reduction of cisplatin resistance. In contrast, overexpression of PCBP4 in IMC-3 cells induced G2/M arrest after cisplatin treatment and enhanced cisplatin resistance. We revealed that PCBP4 combined with Cdc25A and suppressed the expression of Cdc25A, resulting in G2/M arrest. PCBP4 plays important roles in the induction of cisplatin resistance in human maxillary cancers. PCBP4 is a novel molecular target for the therapy of head and neck cancers, especially cisplatin-resistant cancers.
Subject(s)
Cisplatin/pharmacology , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Maxillary Neoplasms/drug therapy , Maxillary Neoplasms/genetics , RNA-Binding Proteins/genetics , Apoptosis/drug effects , Apoptosis/genetics , Cell Line, Tumor , DNA Damage/drug effects , DNA Damage/genetics , G2 Phase Cell Cycle Checkpoints/drug effects , G2 Phase Cell Cycle Checkpoints/genetics , Humans , M Phase Cell Cycle Checkpoints/drug effects , M Phase Cell Cycle Checkpoints/genetics , Signal Transduction/drug effects , Signal Transduction/genetics , cdc25 Phosphatases/geneticsABSTRACT
Mice deficient for Id2, a negative regulator of basic helix-loop-helix (bHLH) transcription factors, exhibit a defect in lactation due to impaired lobuloalveolar development during pregnancy, similar to the mice lacking the CCAAT enhancer binding protein (C/EBP) beta. Here, we show that Id2 is a direct target of C/EBPbeta. Translocation of C/EBPbeta into the nucleus, which was achieved by using a system utilizing the fusion protein between C/EBPbeta and the ligand-binding domain of the human estrogen receptor (C/EBPbeta-ERT), demonstrated the rapid induction of endogenous Id2 expression. In reporter assays, transactivation of the Id2 promoter by C/EBPbeta was observed and, among three potential C/EBPbeta binding sites found in the 2.3 kb Id2 promoter region, the most proximal element was responsible for the transactivation. Electrophoretic mobility shift assay (EMSA) identified this element as a core sequence to which C/EBPbeta binds. Chromatin immunoprecipitation (ChIP) furthermore confirmed the presence of C/EBPbeta in the Id2 promoter region. Northern blotting showed that Id2 expression in C/EBPbeta-deficient mammary glands was reduced at 10 days post coitus (d.p.c.), compared with that in wild-type mammary glands. Thus, our data demonstrate that Id2 is a direct target of C/EBPbeta and provide insight into molecular mechanisms underlying mammary gland development during pregnancy.
